Objective: The antifungal activity of a new water soluble polyene, corifungin, was evaluated against clinical strains of Candida species. Methods: In vitro evaluation of corifungin was performed and compared to amphotericin B deoxycholate (AmB) against 35 different strains of Candida which included C. albicans (5), C. krusei (5), C. tropicalis (5), C. lusitaniae (5), C. glabrata (5), C. dubliniensis (5). This included several C. glabrata strains with multi-drug resistance patterns. In-vitro evaluation was performed using the CLSI standards and read at 48 hrs. Results: The mean minimal inhibitory concentration (MIC) of corifungin and AmB for C. albicans was 0.5 Âµg/ml and 0.5 Âµg/ml, respectively, for C. tropicalis 0.5 and 1Âµg/ml, for C. dubliniensis 0.125 and 0.5 Âµg/ml, for C. parapsilosis 0.5 and 1Âµg/ml, for C. lusitaniae 0.5 and 1.0 Âµg/ml, for C. krusei 2 and 1 Âµg/ml, and for C. glabrata 0.5 and 1.0 Âµg/ml, respectively. Conclusion: The results indicate that corifungin demonstrated excellent in vitro antifungal activity with low MICs against the most common Candida species, with slightly less activity against C. krusei. In addition, corifungin also demonstrated good activity against the several multi-azole resistant C. glabrata species. Corifungin appears to be an excellent candidate for the treatment of candidal infections.
Full conference title:
19th European Congress of Clinical Microbiology and Infectious Diseases
- ECCMID 19th (2009)